Ascendis Pharma A/S (NASDAQ:ASND) Shares Sold by Fred Alger Management LLC

Fred Alger Management LLC decreased its holdings in Ascendis Pharma A/S (NASDAQ:ASND) by 15.9% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 258,210 shares of the biotechnology company’s stock after selling 48,863 shares during the period. Fred Alger Management LLC owned about 0.43% of Ascendis Pharma A/S worth $38,553,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also modified their holdings of the company. Loomis Sayles & Co. L P grew its stake in shares of Ascendis Pharma A/S by 35.3% in the third quarter. Loomis Sayles & Co. L P now owns 184,623 shares of the biotechnology company’s stock worth $27,566,000 after acquiring an additional 48,120 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its stake in shares of Ascendis Pharma A/S by 63.8% in the third quarter. China Universal Asset Management Co. Ltd. now owns 11,142 shares of the biotechnology company’s stock worth $1,664,000 after acquiring an additional 4,338 shares in the last quarter. Evolutionary Tree Capital Management LLC grew its stake in shares of Ascendis Pharma A/S by 82.3% in the second quarter. Evolutionary Tree Capital Management LLC now owns 24,862 shares of the biotechnology company’s stock worth $3,391,000 after acquiring an additional 11,223 shares in the last quarter. SG Americas Securities LLC grew its stake in shares of Ascendis Pharma A/S by 221.0% in the second quarter. SG Americas Securities LLC now owns 6,108 shares of the biotechnology company’s stock worth $833,000 after acquiring an additional 4,205 shares in the last quarter. Finally, First Turn Management LLC grew its stake in shares of Ascendis Pharma A/S by 23.1% in the second quarter. First Turn Management LLC now owns 186,581 shares of the biotechnology company’s stock worth $25,446,000 after acquiring an additional 34,994 shares in the last quarter.

Ascendis Pharma A/S Price Performance

Shares of ASND opened at $136.32 on Friday. Ascendis Pharma A/S has a 1-year low of $90.13 and a 1-year high of $161.00. The stock has a market cap of $8.27 billion, a PE ratio of -16.87 and a beta of 0.66. The firm has a fifty day moving average price of $132.21 and a 200 day moving average price of $132.24.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its earnings results on Tuesday, September 3rd. The biotechnology company reported ($2.05) EPS for the quarter, missing analysts’ consensus estimates of ($1.54) by ($0.51). The firm had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. As a group, equities analysts expect that Ascendis Pharma A/S will post -7.45 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have commented on ASND shares. Evercore ISI boosted their price target on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 17th. TD Cowen decreased their price objective on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. JPMorgan Chase & Co. decreased their price objective on shares of Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating for the company in a research report on Wednesday, October 23rd. Oppenheimer decreased their price objective on shares of Ascendis Pharma A/S from $190.00 to $180.00 and set an “outperform” rating for the company in a research report on Friday, November 15th. Finally, Stifel Nicolaus lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research report on Friday, November 15th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.